<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    14984370
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     02
    </month>
    <day>
     26
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     04
    </month>
    <day>
     16
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2007
    </year>
    <month>
     11
    </month>
    <day>
     15
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0269-2813
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       19
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        Feb
       </month>
       <day>
        1
       </day>
      </pubdate>
     </journalissue>
     <title>
      Alimentary pharmacology &amp; therapeutics
     </title>
     <isoabbreviation>
      Aliment. Pharmacol. Ther.
     </isoabbreviation>
    </journal>
    <articletitle>
     Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome.
    </articletitle>
    <pagination>
     <medlinepgn>
      245-51
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Both high-fibre dietary advice and the prescription of fibre as a bulking agent are very common in primary and secondary care management of irritable bowel syndrome. Irritable bowel syndrome patients with constipation may have delayed intestinal transit. Therefore, fibres that accelerate intestinal transit may be beneficial in these patients. The uncertain benefits reported in several clinical studies, however, have led us to reappraise the value of fibre in irritable bowel syndrome management.
     </abstracttext>
     <abstracttext label="AIM" nlmcategory="OBJECTIVE">
      To quantify the effect of different types of fibre on global and symptom relief from irritable bowel syndrome.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Using a structured literature search in MEDLINE (1966-2002), we selected randomized controlled trials involving irritable bowel syndrome patients treated with fibre. Analyses were performed for the total group and for trials using soluble and insoluble fibre separately.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Seventeen studies were included in the analysis. None investigated primary care irritable bowel syndrome patients. Fibre, in general, was effective in the relief of global irritable bowel syndrome symptoms [relative risk, 1.33; 95% confidence interval (CI), 1.19-1.50]. Irritable bowel syndrome patients with constipation may receive benefit from fibre treatment (relative risk, 1.56; 95% CI, 1.21-2.02), but there was no evidence that fibre was effective in the relief of abdominal pain in irritable bowel syndrome. Soluble and insoluble fibre, separately, had different effects on global irritable bowel syndrome symptoms. Soluble fibre (psyllium, ispaghula, calcium polycarbophil) showed significant improvement (relative risk, 1.55; 95% CI, 1.35-1.78), whereas insoluble fibre (corn, wheat bran), in some cases, worsened the clinical outcome, but there was no significant difference compared with placebo (relative risk, 0.89; 95% CI, 0.72-1.11).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      The benefits of fibre in the treatment of irritable bowel syndrome are marginal for global irritable bowel syndrome symptom improvement and irritable bowel syndrome-related constipation. Soluble and insoluble fibres have different effects on global irritable bowel syndrome symptoms. Indeed, in some cases, insoluble fibres may worsen the clinical outcome. Future clinical studies evaluating the effect and tolerability of fibre therapy are needed in primary care.
     </abstracttext>
    </abstract>
    <affiliation>
     Utrecht University Medical Center, Julius Center for Primary Care and Health Sciences, Utrecht, The Netherlands.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Bijkerk
      </lastname>
      <forename>
       C J
      </forename>
      <initials>
       CJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Muris
      </lastname>
      <forename>
       J W M
      </forename>
      <initials>
       JW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Knottnerus
      </lastname>
      <forename>
       J A
      </forename>
      <initials>
       JA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hoes
      </lastname>
      <forename>
       A W
      </forename>
      <initials>
       AW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       de Wit
      </lastname>
      <forename>
       N J
      </forename>
      <initials>
       NJ
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     Aliment Pharmacol Ther
    </medlineta>
    <nlmuniqueid>
     8707234
    </nlmuniqueid>
    <issnlinking>
     0269-2813
    </issnlinking>
   </medlinejournalinfo>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Colonic Diseases, Functional
     </descriptorname>
     <qualifiername majortopicyn="Y">
      diet therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dietary Fiber
     </descriptorname>
     <qualifiername majortopicyn="N">
      analysis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    43
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      2
     </month>
     <day>
      27
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      4
     </month>
     <day>
      17
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      2
     </month>
     <day>
      27
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     14984370
    </articleid>
    <articleid idtype="pii">
     1862
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

